Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Benlysta Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Benlysta (belimumab) Coverage Criteria

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and reauthorization criteria for subcutaneous Benlysta in patients aged 5 years and older with systemic lupus erythematosus or active lupus nephritis receiving standard therapy.

    Policy Summary
    PayerUnitedHealthcare
    PolicyBenlysta (belimumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual reviewno material clinical or coverage changes
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionDocument the applicable diagnosis, standard immunosuppressive therapy, and any required positive response for reauthorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5+Minimum patient age
    2Covered indications
    12 moInitial authorization
    12 moReauthorization
    4

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Prohibited combination drugs

    Covered Indications and Exclusions

    Initial therapy: systemic lupus erythematosus

    Covered for initial therapy when ALL of the following are met.

    Systemic lupus erythematosus initial therapy

    • Diagnosis: The patient has a diagnosis of systemic lupus erythematosus.
    • Concurrent standard therapy: The patient is currently receiving standard immunosuppressive therapy, such as hydroxychloroquine, chloroquine, prednisone, azathioprine, or methotrexate.
    • CNS lupus exclusion: The patient does not have severe active central nervous system lupus.
    • Combination therapy exclusion: The patient is not receiving Benlysta in combination with Saphnelo (anifrolumab-fnia) for treatment of the same indication.

    Continuation therapy: systemic lupus erythematosus

    Covered for reauthorization when ALL of the following are met.

    Systemic lupus erythematosus reauthorization

    • Clinical response: Documentation of positive clinical response to Benlysta therapy.
    • Combination therapy exclusion: The patient is not receiving Benlysta in combination with Saphnelo (anifrolumab-fnia) for treatment of the same indication.

    Initial therapy: active lupus nephritis

    Covered for initial therapy when ALL of the following are met.

    Active lupus nephritis initial therapy

    • Diagnosis: The patient has a diagnosis of active lupus nephritis.
    • Concurrent standard therapy: The patient is currently receiving standard immunosuppressive therapy for systemic lupus erythematosus, such as hydroxychloroquine, chloroquine, prednisone, azathioprine, or methotrexate.
    • CNS lupus exclusion: The patient does not have severe active central nervous system lupus.
    • Combination therapy exclusion: The patient is not receiving Benlysta in combination with Lupkynis (voclosporin), Saphnelo (anifrolumab-fnia), or Gazyva (obinutuzumab) to treat the same indication.

    Continuation therapy: active lupus nephritis

    Covered for reauthorization when ALL of the following are met.

    Active lupus nephritis reauthorization

    • Clinical response: Documentation of positive clinical response to Benlysta therapy.
    • Combination therapy exclusion: The patient is not receiving Benlysta in combination with Lupkynis (voclosporin), Saphnelo (anifrolumab-fnia), or Gazyva (obinutuzumab) to treat the same indication.

    Severe active central nervous system (CNS) lupus is excluded from recommended Benlysta use and the initial coverage criteria. Efficacy has not been evaluated in this population, and Benlysta is not recommended when severe active CNS lupus is present.

    Concurrent use of Benlysta with specified therapies for the same indication is excluded. For systemic lupus erythematosus, Benlysta must not be used with Saphnelo (anifrolumab-fnia). For active lupus nephritis, Benlysta must not be used with Lupkynis (voclosporin), Saphnelo (anifrolumab-fnia), or Gazyva (obinutuzumab).

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization: Systemic Lupus Erythematosus

    Initial authorization for systemic lupus erythematosus (SLE) requires all criteria below. Authorization will be issued for 12 months.

    • Diagnosis of systemic lupus erythematosus
    • Currently receiving standard immunosuppressive therapy, such as hydroxychloroquine, chloroquine, prednisone, azathioprine, or methotrexate
    • Does not have severe active central nervous system lupus
    • Is not receiving Benlysta in combination with Saphnelo (anifrolumab-fnia) for treatment of the same indication
    Prior Authorization

    Reauthorization: Systemic Lupus Erythematosus

    Reauthorization for SLE requires both documentation of a positive clinical response to Benlysta and confirmation that Benlysta is not being used with Saphnelo for the same indication. Authorization will be issued for 12 months.

    • Document positive clinical response to Benlysta therapy

    Policy Background

    Benlysta (belimumab) is a B-lymphocyte stimulator (BLyS)-specific inhibitor. The policy covers patients aged 5 years and older who are receiving standard therapy for active systemic lupus erythematosus (SLE) or active lupus nephritis. Efficacy has not been evaluated in patients with severe active CNS lupus, and use is not recommended in that setting.

    Key Terms

    Definitions
    TermBenlysta
    ClassB-lymphocyte stimulator (BLyS)-specific inhibitor
    Covered useUsed for patients aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis who are receiving standard therapy
    Definitions
    AbbreviationSLE
    Full nameSystemic lupus erythematosus
    Covered contextActive SLE in patients aged 5 years and older who are receiving standard therapy

    Initial Therapy by Indication

    Systemic lupus erythematosus

    Initial therapy requires ALL of the following criteria.

    Systemic lupus erythematosus initial therapy

    • Diagnosis: The patient has a diagnosis of systemic lupus erythematosus.
    • Concurrent standard therapy: The patient is currently receiving standard immunosuppressive therapy, such as hydroxychloroquine, chloroquine, prednisone, azathioprine, or methotrexate.
    • CNS lupus exclusion: The patient does not have severe active central nervous system lupus.
    • Combination therapy exclusion:

    Reauthorization by Indication

    Systemic lupus erythematosus reauthorization

    Reauthorization is covered when both of the following criteria are met.

    • Clinical response: Documentation of positive clinical response to Benlysta therapy.
    • Combination therapy exclusion: The patient is not receiving Benlysta in combination with Saphnelo (anifrolumab-fnia) for treatment of the same indication.

    Active lupus nephritis reauthorization

    Reauthorization is covered when both of the following criteria are met.

    • Clinical response:
    Policy Summary
    PayerUnitedHealthcare
    PolicyBenlysta (belimumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual reviewno material clinical or coverage changes
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionDocument the applicable diagnosis, standard immunosuppressive therapy, and any required positive response for reauthorization.
    SourceLink
    On This Page
    Covered Indications and ExclusionsAuthorization and Documentation RequirementsPolicy BackgroundKey TermsInitial Therapy by IndicationReauthorization by Indication
  1. Confirm the patient is not receiving Benlysta in combination with Saphnelo (anifrolumab-fnia) for treatment of the same indication
  2. Prior Authorization

    Initial Authorization: Active Lupus Nephritis

    Initial authorization for active lupus nephritis requires all criteria below. Authorization will be issued for 12 months.

    • Diagnosis of active lupus nephritis
    • Currently receiving standard immunosuppressive therapy for SLE, such as hydroxychloroquine, chloroquine, prednisone, azathioprine, or methotrexate
    • Does not have severe active central nervous system lupus
    • Is not receiving Benlysta in combination with any of the following to treat the same indication: Lupkynis (voclosporin), Saphnelo (anifrolumab-fnia), or Gazyva (obinutuzumab)
    Prior Authorization

    Reauthorization: Active Lupus Nephritis

    Reauthorization for active lupus nephritis requires both documentation of a positive clinical response to Benlysta and confirmation that prohibited combination therapy is not being used. Authorization will be issued for 12 months.

    • Document positive clinical response to Benlysta therapy
    • Confirm Benlysta is not being used in combination with Lupkynis (voclosporin), Saphnelo (anifrolumab-fnia), or Gazyva (obinutuzumab) to treat the same indication
    Documentation Required

    Initial Clinical Documentation

    For initial authorization, document the applicable diagnosis and the patient's concurrent standard immunosuppressive therapy.

    • For SLE: document a diagnosis of systemic lupus erythematosus
    • For active lupus nephritis: document a diagnosis of active lupus nephritis
    • Document current standard immunosuppressive therapy, such as hydroxychloroquine, chloroquine, prednisone, azathioprine, or methotrexate
    Documentation Required

    Reauthorization Documentation

    For reauthorization, document a positive clinical response to Benlysta and confirm that the patient is not receiving prohibited combination therapy for the same indication.

    • Document positive clinical response to Benlysta therapy
    • Confirm no prohibited same-indication combination therapy is being used
    Denial Risk

    Denial Risk: Severe Active CNS Lupus

    Coverage may be denied when the patient has severe active central nervous system lupus. This exclusion applies to initial authorization for SLE and active lupus nephritis.

    • Screen for and document the absence of severe active central nervous system lupus before requesting initial authorization
    Denial Risk

    Denial Risk: Prohibited Combination Therapy

    Coverage may be denied when Benlysta is used with a prohibited same-indication therapy. Verify the medication list before initial authorization or reauthorization.

    • For SLE: Saphnelo (anifrolumab-fnia)
    • For active lupus nephritis: Lupkynis (voclosporin)
    • For active lupus nephritis: Saphnelo (anifrolumab-fnia)
    • For active lupus nephritis: Gazyva (obinutuzumab)
    Documentation Required

    Diagnosis and Standard Therapy Required

    Initial authorization requires both the applicable diagnosis and concurrent standard immunosuppressive therapy. The therapy requirement applies to SLE and active lupus nephritis, with lupus nephritis requiring standard immunosuppressive therapy for SLE.

    • Applicable diagnosis must be documented: systemic lupus erythematosus or active lupus nephritis
    • Document current standard immunosuppressive therapy, such as hydroxychloroquine, chloroquine, prednisone, azathioprine, or methotrexate
    The patient is not receiving Benlysta in combination with Saphnelo (anifrolumab-fnia) for treatment of the same indication.

    Active lupus nephritis

    Initial therapy requires ALL of the following criteria.

    Active lupus nephritis initial therapy

    • Diagnosis: The patient has a diagnosis of active lupus nephritis.
    • Concurrent standard therapy: The patient is currently receiving standard immunosuppressive therapy for systemic lupus erythematosus, such as hydroxychloroquine, chloroquine, prednisone, azathioprine, or methotrexate.
    • CNS lupus exclusion: The patient does not have severe active central nervous system lupus.
    • Combination therapy exclusion: The patient is not receiving Benlysta in combination with Lupkynis (voclosporin), Saphnelo (anifrolumab-fnia), or Gazyva (obinutuzumab) to treat the same indication.
    Documentation of positive clinical response to Benlysta therapy.
  3. Combination therapy exclusion: The patient is not receiving Benlysta in combination with Lupkynis (voclosporin), Saphnelo (anifrolumab-fnia), or Gazyva (obinutuzumab) to treat the same indication.